



Leukemia: Present and Future

Guest Editor:

Prof. Dr. Carla Di Stefano

Department of Experimental
Medicine and Surgery, Università
degli Studi di Roma "Tor
Vergata", 00133 Rome, Italy

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Chronic myeloid leukemia (CML) is a malignancy characterized by the clonal proliferation of white blood cells that mostly originate from the myeloid lineage in bone marrow. Approximately 95% of CML patients are diagnosed at the chronic phase (CP), which is relatively indolent but can involve symptoms such as fatigue, abdominal pain, or weight loss. If untreated, the disease can progress to the accelerated phase (AP), which can last for up to a year, and will eventually progress into the terminal blast phase of the disease, termed the blast crisis (BC). Therefore, in this Special Issue, we invited authors to submit original research and review articles. Topics of this Special Issue include, but are not limited to:

- BCR::ABL1-dependent and BCR::ABL1-independent mechanisms of tyrosine kinase inhibitor (TKI) resistance;
- The development of targeted therapies against specific deregulated pathways, such as the alternative activation of the MAPK, JAK/STAT, or PI3K/AKT pathway and of Wnt/ β -catenin signaling.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI